After its $39 billion takeover of Alexion, AstraZeneca has reportedly scuppered an investor group's proposed buyout of another rare disease drugmaker. The company was worried one of its former respiratory meds could be sold to competitors, Bloomberg reports.
Rachel Pegram, who has the rare disease generalized myasthenia gravis, wanted an easier way to explain her condition to her three-year-old daughter. So she worked with AstraZeneca's Alexion unit to create "Klara's Talent," the first in a children's book series to help families discuss rare diseases with their kids.
Bad news has struck first for AstraZeneca’s newly acquired Alexion rare disease franchise. AstraZeneca has decided to cap a trial testing Ultomiris in the rare neurodegenerative disease amyotrophic lateral sclerosis, citing lack of efficacy.